Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cancer drug could aid premature labour

14.06.2005


AN anti-cancer drug could potentially be the first effective treatment for the many thousands of premature births that occur worldwide each year, scientific tests have found.



The drug, which has been used to treat types of cancer including breast, bowel and lung, has been found in the laboratory to control levels of a hormone receptor protein in the womb which is linked with giving birth.

The findings, from a research team at the University of Newcastle upon Tyne, should bring hope to the women who see their premature babies die or suffer from physical or mental disability as a result of being born too early.


The research, funded by the charity Action Medical Research, is published today in the Journal of Clinical Endocrinology and Metabolism.

In the UK each year, around 10 per cent, approximately 60,000, pregnancies end with premature births of less than 37 weeks gestation, which is the highest rate in Western Europe and costs the NHS millions of pounds. The problem is worse in the developing world.

Drugs currently used to treat women who give birth prematurely are relatively ineffective, and often have dangerous side effects, such as heart problems in mother and baby.

The research team examined the effect that the anti-cancer drug Trichostatin A - better known as TSA - had on the levels of receptors on human smooth muscle cells of the womb, or uterus, that are affected by the pregnancy hormone, hCG (Human chorionic gonadotrophin).

During pregnancy, the placenta releases large amounts of hCG. This activates the CG/LH receptors on the muscle cells of the womb to produce a muscle relaxant, which in turn prevents contractions and keeps the uterus in a relaxed state. It is known that decreases in hCG receptor levels may lead to contractions in the womb and labour.

Women whose babies are born prematurely experience an acute drop in the numbers of the CG/LH receptors and are thus less responsive to the hCG hormone. Laboratory tests carried out by the Newcastle University team found that TSA is able to increase numbers of the CG/LH receptors in uterine smooth muscle cells.

The researchers are now seeking funding for clinical trials to assess whether TSA would work in women who are due to give birth prematurely, or in those who are at high risk of having a premature baby.

Research team leader, Dr Nick Europe-Finner, of Newcastle University’s School of Surgical and Reproductive Sciences, said: “Many people think that that premature births are no longer a problem and would be astonished to know that, even in a sophisticated, developed nation like the UK, there are still around 10 per cent of births which are classed as premature.

“It’s particularly frustrating for doctors and mothers alike that there is still no effective treatment, despite the fact that many premature babies die or have physical or mental conditions that may affect them for the rest of their lives.

“Our laboratory tests show that the drug TSA is able to fool uterine muscle cells and suggest it could be a potential new therapeutic agent in preventing premature birth from occurring. We now need to take the research a step further and test it in a clinical setting, although funding for this would be required.”

Mr Andrew Loughney , consultant obstetrician at the Royal Victoria Infirmary in Newcastle upon Tyne, said: “This is a very exciting area of research because it may lead to the development of new, more effective ways of preventing premature birth.

“Premature birth is a huge problem in the UK. In the hospital where I work, the Royal Victoria Infirmary in Newcastle upon Tyne, we find ourselves looking after women in premature labour day in and day out without having any really effective treatments to offer.

“There are two challenges ahead. The first will be to see whether the drug has a clear clinical effect in reducing contractions in the womb. The second will be to ensure that the new treatment has no adverse effects for the mother or the baby.”

Dr Nick Europe-Finner | alfa
Further information:
http://www.ncl.ac.uk

More articles from Health and Medicine:

nachricht New antibody analysis accelerates rational vaccine design
09.08.2018 | Scripps Research Institute

nachricht Distrust of power influences choice of medical procedures
01.08.2018 | Johannes Gutenberg-Universität Mainz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

Im Focus: Lining up surprising behaviors of superconductor with one of the world's strongest magnets

Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur

What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...

Im Focus: World record: Fastest 3-D tomographic images at BESSY II

The quality of materials often depends on the manufacturing process. In casting and welding, for example, the rate at which melts solidify and the resulting microstructure of the alloy is important. With metallic foams as well, it depends on exactly how the foaming process takes place. To understand these processes fully requires fast sensing capability. The fastest 3D tomographic images to date have now been achieved at the BESSY II X-ray source operated by the Helmholtz-Zentrum Berlin.

Dr. Francisco Garcia-Moreno and his team have designed a turntable that rotates ultra-stably about its axis at a constant rotational speed. This really depends...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

2018 Work Research Conference

25.07.2018 | Event News

 
Latest News

'Building up' stretchable electronics to be as multipurpose as your smartphone

14.08.2018 | Information Technology

During HIV infection, antibody can block B cells from fighting pathogens

14.08.2018 | Life Sciences

First study on physical properties of giant cancer cells may inform new treatments

14.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>